The Russian government, through its Skolkovo initiative, has given $5m in grant money to the firm to carry on its oncological research.
Russia-based biopharmaceutical company Incuron obtained a $5m grant from Skolkovo, the Russian government initiative intended to encourage science and technology development, on Monday. Incuron’s research is focused around Curaxins, small molecules designed to combat cancer.
Incuron was formed through a partnership between US-based biotechnology company Cleveland BioLabs, backed by Cleveland Clinics, and the Russia-based venture capital fund Bioprocess Capital Ventures. One of the key investors in Bioprocess is VneshEconomBank, the Russian government-backed investment bank which functions by helping strengthen the…
